04-03-2014, 04:00 PM 
	
	
	
		I've been skeptical of Isis Pharmaceuticals because of the twisted path that its drug Kynamro took to market, at first appearing like it might be a big opportunity and then having expectations repeatedly cut as a competitor emerged.
	
	
	
	

 


![[+]](https://www.biotechnologyforums.com/images/netpen-pro/collapse_collapsed.png)